Adagio Shares Plunge 79% as Antibody Fails In Vitro Studies

Adagio Therapeutics saw its share price plummet 79% Tuesday after it acknowledged the failure of its COVID-19 antibody candidate ADG20 to effectively neutralize the Omicron variant of SARS-CoV-2 (B1.1.529) in lab testing as it publicly theorized late last month.

Related Keywords

South Africa , United States , Lebanon , Tillman Gerngross , K Dane Wittrup , Michael Yee , Brii Bioscience , Laura Walker , Eli Lilly , Astrazeneca , Adagio Therapeutics , Polaris Partners , Google Ventures , Vir Biotechnology , Singlomics Biopharmaceutical ,